Enhancement of radiosensitivity by CpG-Oligodeoxyribonucleotide-7909 in human non-small cell lung cancer A549 cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 2, 2010, Pages 165-170

  Zha, Lin ^a   Qiao, Tiankui ^a   Yuan, Sujuan ^a   Lei, Linjie ^a  

^a JINSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Lung cancer; Oligodeoxyribonucleotides; Radiosensitivity Toll like receptor 9

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE 7909; MESSENGER RNA; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE TIME EFFECT RELATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOSENSITIVITY;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; GAMMA RAYS; HUMANS; LUNG NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TOLL-LIKE RECEPTOR 9; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951954388     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0686     Document Type: Article

References (31)

1. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709.
2. Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev 2008;60:795.
3. Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs 2007;21:387.
4. Jahrsdorfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008;3:27.
5. Hofmann MA, Kors C, Audring H, et al. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008;31:520.
6. Link BK, Ballas ZK, Weisdorf D, et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 2006;29:558.
7. Molenkamp BG, Sluijter BJ, van Leeuwen PA, et al. Local administration of PF-3512676 CpG-B instigates tumorspecific CD8+T-cell reactivity in melanoma patients. Clin Cancer Res 2008;14:4532.
8. Manegold C, Gravenor D, Woytowitz D, et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3979.
9. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008;27:161.
10. Jahrsdorfer B, Jox R, Muhlenhoff L, et al. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 2002;72:83.
11. Tidd DM, Broughton CM, Clark RE. CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis. Nucleic Acids Res 2003;31:2297.
12. Khorramizadeh MR, Hosseinzadeh S, Safavifar F, et al. Interaction of CpG-oligodeoxynucleotides with toll like receptor 9 induces apoptosis and modulates met al.oproteinase-2 activity in human intestinal epithelium. Iran J Allergy Asthma Immunol 2007;6:107.
13. Rayburn ER, Wang W, Zhang R, et al. Experimental therapy for colon cancer: Anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence uponp53. Int J Oncol 2007;30:1511.
14. Wang H, Rayburn ER, Wang W, et al. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting toll-like receptor 9. Mol Cancer Ther 2006;5:1585.
15. Rayburn ER, Wang W, Zhang Z, et al. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: Effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate 2006;66:1653.
16. Jorgensen TJ. Enhancing radiosensitivity: Targeting the DNA repair pathways. Cancer Biol Ther 2009;8:665.
17. Mullen GE, Ellis RD, Miura K, et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CpG 7909: An asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS ONE 2008;3: e2940.
18. Tsutsumi K, Yasuda M, Nishioka T. X-ray radiation altered chemosensitivity of a p53-null non-small cell lung cancer cell line. Cell Struct Funct 2006;31:47.
19. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184.
20. Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 2007;4:289.
21. Xie YF, Sheng W, Xiang J, et al. Adenovirus-mediated ING4 expression suppresses pancreatic carcinoma cell growth via induction of cell-cycle alteration, apoptosis, and inhibition of tumor angiogenesis. Cancer Biother Radiopharm 2009;24:261.
22. Yi T, Li H, Wang X, et al. Enhancement radiosensitization of breast cancer cells by deguelin. Cancer Biother Radiopharm 2008;23:355.
23. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:928.
24. Xu L, Wang C, Wen Z, et al. Selective up-regulation of CDK2 is critical for TLR9 signaling stimulated proliferation of human lung cancer cell. Immunol Lett 2009;2:93.
25. Yan W, Ding FG, Li B, et al. Study of Cp G ODN107 on the radiosensitivity of human glioma cell line CHG25. Zhong Hua Zhong Liu Fang Zhi Za Zhi 2007;14:481.
26. Bauer S, Wagner H. Bacterial CpG-DNA licenses TLR9. Curr Top Microbiol Immunol 2002;270:145.
27. Merrell MA, Ilvesaro JM, Lehtonen N, et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix met al.loproteinase activity. Mol Cancer Res 2006;4:437.
28. Bertin S, Samson M, Pons C, et al. Comparative proteomics study reveals that bacterial CpG motifs induce tumor cell autophagy in vitro and in vivo. Mol Cell Proteomics 2008;7:2311.
29. Meneghin A, Choi ES, Evanoff HL, et al. TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem Cell Biol 2008;130:979.
30. Ilvesaro JM, Merrell MA, Swain TM, et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007;67:774.
31. Fischer SF, Rehm M, Bauer A, et al. Toll-like receptor 9 signaling can sensitize fibroblasts for apoptosis. Immunol Lett 2005;97:115.